ZoomRx Blog

#ESMO26: Practicing oncologists are excited about new treatments but cautious about the realities of implementation

Written by Kinga Zapert | Nov 16, 2026, 3:54:30 AM

Post-congress interviews with oncologists across EU4 and the UK highlight recognition of scientific progress delivered by the conference, along with practical questions about patient selection, testing, sequencing and access.

The #ESMO26 conference concluded in Madrid a few weeks ago. Attended by over 40,000 oncologists, researchers and industry professionals, it was accompanied by a flurry of media and analyst coverage, journal publications, and post-conference industry events. As the attendees returned home, we asked 18 practicing oncologists to reflect on key takeaways from the conference and anticipated impact on their practices short- and longer-term. All the oncologists we interviewed attended ESMO in person and came from 5 major European countries (France, Germany, Italy, Spain and the UK) representing both academic and community settings. All interviews were AI-moderated in local languages, averaged 20-minutes in length and were conducted between October 29 and November 6, 2026.

General sentiment: Positive experience and excitement

Oncologists described the Congress as well-organized and helpful in keeping up with the rapidly changing field of oncology. The reactions to data were positive, highlighting overall progress and expressing enthusiasm for specific sessions that could be practice-changing; only a couple of respondents had a more tempered response.

“A very positive experience with lots of resources that are reliable, very relatable to my daily practice, a very well-organized conference.” – Academic | Medical Oncology | UK

“Overall, it was a very good experience because there was a lot of new data, some of which could change practice in the near term, especially when the treatments are already available in another line.” - Community | Medical Oncology | France

"The experience was positive, although there were no particularly striking data. I had the opportunity to meet international colleagues, speak with pharmaceutical company representatives, and attend some presentations.” - Community | Medical Oncology | Italy

Themes and MOAs that dominated

Antibody-drug conjugates (ADCs) were a major theme mentioned by our respondents who noted the ADC emergence across gynecologic, lung, breast, gastric, and other solid tumors. Oncologists specifically recalled HER2-targeting ADCs in breast cancer, TROP2-directed sacituzumab tirumotecan in endometrial cancer and NSCLC, and CLDN18.2-directed sonesitatug vedotin in gastric cancer among others.

Biomarker-driven approaches to overcoming resistance and renewed interest in KRAS G12C inhibition in NSCLC specifically divarasib were also mentioned. Novel immunotherapies including PD-1 x VEGF bispecific antibodies such as ivonescimab continued to draw attention in NSCLC and beyond. The DLL3-directed T-cell engager, tarlatamab, CAR T-cell approaches, and personalized mRNA neoantigen vaccines were also closely watched at this year's meeting.

“There were many new treatment approaches, particularly antibody-drug conjugates, or ADCs, and precision oncology approaches. Claudin and HER2, as well as CAR T-cell targeted approaches, are playing an increasingly important role.” - Community | Medical Oncology | Germany

“For the first time, a Phase 3 study demonstrated clinical benefit from adding personalized neoantigen therapy to an anti-PD-1 treatment in the adjuvant setting.” - Academic | Medical Oncology | Italy

“The data were important across several tumor types, including melanoma; antibody-drug conjugates in breast cancer; small-cell lung cancer; biliary tract cancer; kidney cancer; and osteosarcoma. Artificial intelligence was particularly noteworthy.” - Academic | Medical Oncology | Italy

“The study evaluated the efficacy and safety of ivonescimab, a bispecific antibody, in combination with chemotherapy compared with durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer.” - Academic | Medical Oncology | Italy

Across treatment approaches, tumors and disease stages, oncologists reflected on ongoing discussions about which patients may benefit, how to identify them, and when the various treatment options should be used and how they should be sequenced.

“For Claudin-positive patients who receive immunotherapy in first line, we could not use the drug or another Claudin-targeted therapy in second line. The ADC closes that gap.” - Community | Medical Oncology | Germany

“Absolutely. I can see an opportunity to act earlier in the treatment course and treat patients appropriately, particularly by screening HER2-positive patients early and starting first-line treatment.” - Community | Medical Oncology | Germany

Perhaps not surprisingly, AI was noted as a trending topic as well, with dozens of sessions about the growing impact of generative AI and autonomous technologies across research and clinical practice.

“HER2-targeted ADCs are good options for patients with various solid tumors, including breast, head and neck, and prostate cancers. Digitalization is ongoing and AI is advancing, so that presentation was very important” - Academic | Hematological Oncology | Germany

“Targeting DLL3 really statistically and clinically improves survival for patients with extensive-stage lung cancer versus anti-PD-L1 alone. So this is potentially changing as a new paradigm, especially using a T-cell engager.” – Academic | Medical Oncology | UK

“The sessions with the greatest impact were the one on using HER2-targeted ADCs in solid tumors and the one on expert strategies for advancing biomarker testing. For the longer term, I would highlight the educational symposium on AI and digital health.” - Academic | Hematological Oncology | Germany

Trials with the highest reported familiarity

DESTINY-Lung04 received the highest Top-3-Box familiarity rating perhaps because the ESMO presentation involved an update to the trial data that was originally presented at an earlier conference, followed by DeLLphi-305, SAFFRON, OptiTROP-Lung04, with other sessions closely behind.

Key-session deep dives: Practice-changing outcomes

We highlight three sessions that captured oncologists' attention as being potentially practice changing: (1) DeLLphi-305 for moving the overall survival milepost in Extensive Stage SCLC beyond what the Immunotherapy strategies alone were able to achieve; (2) SAFFRON for offering targeted approach to overcome resistance to 3rd generation TKIs in EGFRm NSCLC; and (3) INTerpath-001 for proving that individualized mRNA cancer vaccines provide benefit in adjuvant melanoma.

DeLLphi-305: A rare moment of progress in extensive stage SCLC

DeLLphi-305 is a Phase III trial from Amgen that evaluated tarlatamab plus durvalumab first-line (1L) maintenance versus durvalumab alone following induction chemoimmunotherapy (durvalumab + etoposide +carbo/cisplatin). While it was known that the data would be positive, the magnitude of the OS and PFS benefit exceeded expectations and the presentation concluded with a standing ovation at the Presidential Session.

All 8 respondents who discussed this session called it potentially practice-changing driven by the significant improvement in median overall survival from 12.7 months to 21.1 months. All 8 respondents highlighted the OS benefit as meaningful and more positive than what they have become accustomed to in this disease.

Nearly all agreed that the DeLLphi-305 regimen would likely displace or even replace the IMforte regimen (atezolizumab plus lurbinectedin) citing better outcomes and fewer hematologic toxicities, along with a novel mechanism as their main reasons.

Oncologists believe that the DeLLphi-305 would be appropriate for patients who are eligible for an IO maintenance and who are fit, performance status ECOG 0-1 and without the relevant contraindications or comorbidities. They don’t anticipate that the pool of eligible patients would expand since the trial was limited to those patients who did not progress following 1L induction.

Open questions remained around the administration and monitoring that would be required for tarlatamab, and even though the presentation suggested that the monitoring requirements in 1L maintenance were less stringent than in later lines of therapy, some remained concerned about the potential burden of the monitoring requirements. These concerns were not deal-breakers and were partly assuaged by the fact that both therapies in the regimen were familiar and currently available. The cost and availability of the DeLLphi-305 regimen were a shared concern with tarlatamab being viewed as an expensive drug.

The bottom-line: Oncologists see DeLLphi-305 as practice-changing and they would adopt it as their new standard of care in 1L maintenance once approved and available.

“I was quite impressed by the [DeLLphi-305] results, which were very significant. They could make tarlatamab plus durvalumab a strongly recommended maintenance regimen. […] Median overall survival is already 21 months, exceeding 20 months—a result we would never have expected in this serious cancer. The 58% reduction in the risk of death is very significant and makes this a new standard.” - Community | Medical Oncology | France

“Patients with extensive-stage disease who have not progressed after first-line induction therapy. They should be in good general condition.” - Academic | Medical Oncology | Italy

“It will certainly change my practice, and will also make it more challenging in some ways, because a monitoring system will need to be put in place for all patients receiving the drug.” - Academic | Medical Oncology | Italy

“One unresolved issue is the lack of a comparison with immunotherapy plus lurbinectedin, although this treatment is probably less toxic overall.” - Academic | Medical Oncology | Italy

“We need to wait for funding and understand that this is something which we can scale up and give to more patients, particularly how to manage CRS and what the pathways are that would change in what we do currently.” - Academic | Medical Oncology | UK

SAFFRON: targets osimertinib resistance but the MET testing requirement could be a bottleneck

This AstraZeneca-funded SAFFRON trial is the first global Phase III evidence that dual EGFR-MET inhibition improves both PFS and OS after progression on 1L osimertinib, potentially establishing a new standard of care for MET-driven resistance in EGFR-mutated NSCLC.

Of 10 oncologists who discussed this trial, virtually all had a positive reaction highlighting the improvements in mPFS and especially the mOS benefit. A few believe that its efficacy is comparable to the benefits of MARIPOSA-2 and that it's far less complex to administer than the amivantamab+ chemotherapy regimen. The oncologists also appreciate that the SAFFRON regimen is chemo-free. However, others feel that these trials should not be compared since the patient populations were different.

The study makes a repeat molecular testing at progression a must and while the majority of our respondents expressed appreciation for the targeted approach and a full intent to test all of their patients for MET at progression, there were also some concerns about the feasibility of new biopsies following 1L progression.

Open questions remain about how the new combination will fit with the evolving 1L and 2L approaches in EGFRm NSCLC. The SAFFRON trial did not provide comparison to some of the current 2L approaches that already include MET-directed Amivantamab combinations. Also, current 1L approaches evolved beyond osimertinib monotherapy especially in the US, and it's not clear how SAFFRON would fit after FLAURA2 or MARIPOSA.

The bottom line: Oncologists see a meaningful role for the SAFFRON regimen in their patients with MET-overexpressed / amplified disease after progression on osimertinib. However, consistent adoption in their practices will require new routines around re-biopsy and a robust MET testing infrastructure.

“I had a very positive impression. Savolitinib combined with osimertinib after progression in EGFR-mutated non-small cell lung cancer with MET amplification or overexpression reduced the risk of progression by about 45% and the risk of death by 30% to 35% compared with the previous platinum and pemetrexed chemotherapy regimen. These are significant overall survival results for an important unmet need, and the regimen appears to perform better than amivantamab plus chemotherapy.” - Community | Medical Oncology | France

“This treatment allows us to continue using an oral combination in patients who have progressed while on osimertinib. It changes my approach by allowing me to avoid chemotherapy.” - Community | Medical Oncology | Italy

“After progression on osimertinib, I think we should perform molecular profiling, including MET testing. If MET overexpression or amplification is found, this offers the opportunity for a very interesting biomarker-directed treatment.” - Community | Medical Oncology | Germany

“The SAFFRON data are extremely interesting, with an improvement of about five months in overall survival. Combining savolitinib with osimertinib, which is already prescribed first line, offers the possibility of highly individualized patient management. The challenge of this new treatment strategy is the need to re-biopsy patients when their disease progresses to confirm MET overexpression. The results of SAFFRON are good news for patients, but they are a challenge for clinicians, who will need to be more insistent about re-biopsying patients at progression.” - Academic | Medical Oncology (Thoracic Oncology) | France

“The SANOVO study was also presented and showed a benefit from adding savolitinib to osimertinib in the first line. We will therefore need to clarify where to position this drug: either in the second line, if SAFFRON is considered more useful, or in the first line for patients who already have MET overexpression and therefore would not be able to receive this treatment strategy in the second line.” - Academic | Medical Oncology (Thoracic Oncology) | France

INTerpath-001: Successful proof of concept, but questions remain

The Phase III INTerpath-001 study was one of the most anticipated ESMO sessions, with the buzz and premature release of data preceding the actual presentation. The study evaluated individualized mRNA neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone in resected Stage IIB-IV melanoma. The novel regimen reduced the risk of recurrence or death by 42% and reduced the risk of distant metastasis or death by 38%, providing the strongest validation to date for personalized cancer vaccine technology.

Oncologists who discussed this session recognized that this is the first time that any modality improved the outcomes above and beyond PD-1 monotherapy. Some also appreciated the individualized design of the vaccine that uses sequencing information from the patient’s tumor and normal DNA to design an individualized mRNA therapy encoding selected tumor neoantigens, and they believe that the vaccine does address an important unmet need.

However, our respondents were split on whether the study represents a shift in the standard of care in adjuvant melanoma. Some oncologists felt that the results were practice-changing, while others would need to see the OS benefit to fully adopt. In addition to immature OS data, oncologists also expressed uncertainty about the costs and logistical feasibility of producing and delivering an individualized therapy beyond a clinical-trial setting.

“The main takeaway was that this is a Phase 3 study in which individualized mRNA neoantigen therapy plus pembrolizumab substantially reduces the risk of recurrence after surgery in patients with high-risk melanoma. The results were presented after a median follow-up of 24.6 months, and the combination met the primary endpoint. The risk of recurrence or death fell by 42% compared with pembrolizumab alone.” - Academic | Hematological Oncology | Germany

“We still need treatments for adjuvant melanoma, and this could have a very positive effect on patients. However, achieving more durable remission remains an issue.” - Academic | Hematological Oncology | Germany

“In resected melanoma, there was a significant overall survival benefit when intismeran was combined with pembrolizumab versus pembrolizumab alone.” - Academic | Medical Oncology | Germany

“One thing which it didn’t show is that it is any better than what I think is the current standard of care, which is neoadjuvant.” - Academic | Medical Oncology | UK

“Probably take 1 or 2 years depending on funding and depends on how feasible it is to scale up this Neoantigen vaccine approach.” - Academic Medical Oncology | UK

Closing

We owe it to our patients to move faster. Cancer is a race against time. This striking statement was presented by one of the invited discussants at the ESMO Presidential session I to highlight the urgency of accelerating oncology innovation and translating scientific advances into improved outcomes for patients. Oncologists we interviewed shared this sentiment by expressing the need to overcome the cost, logistical and access barriers and bring the much-needed new efficacious treatments to their patients sooner.